FDA Issues Warning Letter to API Manufacturer Apotex Pharmachem India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Warning Letter to API Manufacturer Apotex Pharmachem India

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

FDA issued a warning letter to Apotex Pharmachem India on June 16, 2014 for cGMP violations for API manufacturing that FDA identified in an inspection of the Bangalore, India plant from Jan. 27 to Jan. 31, 2014. FDA cited failure to maintain complete data from laboratory tests, failure to investigate and document out-of-specification results, failure to include adequate documentation during complaint investigation, and failure to record activities at the time they are performed. In issuing the warning, FDA noted that the firm's response lacked sufficient corrective actions.

Regarding laboratory data problems, FDA noted a "general lack of reliability and accuracy of data generated by your firm's laboratory, which is a serious cGMP deficiency that raises concerns about the integrity of all data generated by your firm." FDA noted that the failure to create and maintain accurate documentation was a repeat observation reported to the facility during inspections in 2006 and 2010. The failure to perform adequate investigations of out-of-specification results had also been reported during these previous inspections.

FDA also noted that the company had been cited in 2010 inspections for failing to include adequate documentation during complaint investigations, and that the company did not implement the corrective actions it had committed to at that time. FDA called for the company to "explain the failure of your firm’s complaint system and how you will implement proper management oversight to ensure adequate corrections to this deficiency."

FDA found that "staff used 'finished product reports review data' worksheets to document critical laboratory information days after the actual testing was performed." FDA said that the examples found "raise serious concerns regarding the integrity, reliability, and accuracy of the data generated and available" at the facility.

Source: FDA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here